KeyCorp Lowers Doximity (NASDAQ:DOCS) Price Target to $70.00

Doximity (NASDAQ:DOCS - Free Report) had its price target cut by KeyCorp from $83.00 to $70.00 in a research note released on Wednesday morning, Marketbeat reports. They currently have an overweight rating on the stock.

Several other research firms also recently weighed in on DOCS. Canaccord Genuity Group upped their price objective on shares of Doximity from $60.00 to $71.00 and gave the stock a "hold" rating in a report on Friday, February 7th. Truist Financial dropped their target price on Doximity from $65.00 to $58.00 and set a "hold" rating on the stock in a report on Thursday, April 10th. Mizuho lifted their price target on Doximity from $55.00 to $65.00 and gave the company a "neutral" rating in a research report on Monday, February 10th. Needham & Company LLC upped their price objective on Doximity from $65.00 to $82.00 and gave the company a "buy" rating in a report on Friday, February 7th. Finally, Stephens started coverage on Doximity in a report on Friday, December 20th. They set an "equal weight" rating and a $55.00 target price on the stock. Eleven investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $65.00.

Doximity Trading Down 4.0 %

NASDAQ:DOCS traded down $2.11 during mid-day trading on Wednesday, hitting $51.10. The stock had a trading volume of 726,324 shares, compared to its average volume of 1,980,135. The company has a 50 day simple moving average of $62.97 and a 200-day simple moving average of $55.92. The stock has a market capitalization of $9.54 billion, a price-to-earnings ratio of 51.10, a P/E/G ratio of 4.10 and a beta of 1.41. Doximity has a 52 week low of $22.96 and a 52 week high of $85.21.

Insiders Place Their Bets

In related news, Director Timothy S. Cabral sold 20,000 shares of the firm's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $57.62, for a total transaction of $1,152,400.00. Following the completion of the sale, the director now directly owns 6,360 shares in the company, valued at approximately $366,463.20. This trade represents a 75.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 37.40% of the company's stock.

Institutional Investors Weigh In On Doximity

Institutional investors have recently modified their holdings of the stock. QSV Equity Investors LLC boosted its position in Doximity by 0.3% during the fourth quarter. QSV Equity Investors LLC now owns 60,763 shares of the company's stock valued at $3,244,000 after purchasing an additional 186 shares during the last quarter. Handelsbanken Fonder AB raised its position in Doximity by 0.7% during the fourth quarter. Handelsbanken Fonder AB now owns 29,700 shares of the company's stock valued at $1,586,000 after acquiring an additional 200 shares in the last quarter. UMB Bank n.a. lifted its stake in Doximity by 69.1% in the fourth quarter. UMB Bank n.a. now owns 575 shares of the company's stock valued at $31,000 after acquiring an additional 235 shares during the last quarter. Fielder Capital Group LLC increased its stake in shares of Doximity by 4.5% during the 4th quarter. Fielder Capital Group LLC now owns 5,488 shares of the company's stock worth $293,000 after purchasing an additional 235 shares during the last quarter. Finally, Larson Financial Group LLC raised its holdings in shares of Doximity by 49.4% during the 4th quarter. Larson Financial Group LLC now owns 756 shares of the company's stock valued at $40,000 after purchasing an additional 250 shares in the last quarter. Institutional investors and hedge funds own 87.19% of the company's stock.

About Doximity

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.